TY  - JOUR
AU  - Mahmoud, Osama
AU  - Püllen, Lukas
AU  - Umutlu, Lale
AU  - Szarvas, Tibor
AU  - Fendler, Wolfgang P
AU  - Ting, Saskia
AU  - Reis, Henning
AU  - Bayer, Henning
AU  - Herrmann, Ken
AU  - Hadaschik, Boris A
AU  - Al-Nader, Mulham
AU  - Berliner, Christoph
TI  - Multitracer comparison of gold standard PSMA-PET/CT with 68Ga-FAPI and 18F-FDG in high-risk prostate cancer: a proof-of-concept study.
JO  - European journal of nuclear medicine and molecular imaging
VL  - nn
SN  - 1619-7070
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - DKFZ-2025-01116
SP  - nn
PY  - 2025
N1  - epub
AB  - The aim of this study was to, evaluate the diagnostic accuracy of [⁶⁸Ga]Ga-FAPI-46 positron emission tomography (PET)/computed tomography (CT) in high-risk prostate cancer (PC) compared to [¹⁸F]PSMA / [⁶⁸Ga]Ga- PSMA- and [¹⁸F]FDG- PET/CT as well as multiparametric magnetic resonance imaging (MRI).Ten patients with high-risk PC (PSA > 20 ng/mL, Gleason score > 7, or > T2c) underwent PET/CT imaging using [⁶⁸Ga]Ga-FAPI-46, [¹⁸F]F-/[⁶⁸Ga]Ga-PSMA and [¹⁸F]FDG before radical prostatectomy (RP). The maximum standardized uptake values (SUVmax) were measured for the entire prostate and individual prostate sextants. Diagnostic accuracy was assessed per patient and per segment by correlating imaging findings with final histopathologic results. Immunohistochemical analysis of PSMA and FAP expression was performed on the index tumor lesion.Histopathologic analysis confirmed pT2c and pT3 prostate adenocarcinoma in 4 (40
KW  - Fibroblast activation protein (Other)
KW  - Fluorodeoxyglucose F18 (Other)
KW  - Positron emission tomography (Other)
KW  - Prostate neoplasms (Other)
KW  - Prostate-specific membrane antigen (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40423777
DO  - DOI:10.1007/s00259-025-07352-6
UR  - https://inrepo02.dkfz.de/record/301724
ER  -